The Evolution of Obesity Pharmacotherapy in Primary Care

The landscape of obesity treatment has undergone a dramatic transformation over the last few years, primarily driven by the emergence of glucagon-like peptide-1 (GLP-1) receptor agonists. Among these, semaglutide has stood out as a cornerstone therapy, showing remarkable efficacy in clinical trials. However, the transition from controlled research environments to daily clinical practice often reveals unique challenges. In the context of real-world semaglutide weight management, practitioners frequently encounter variables that were not present in the Phase 3 STEP trials. These include financial barriers, varying patient motivations, and differing levels of clinician experience with dose-escalation protocols. Understanding how these factors influence outcomes is vital for clinicians who aim to provide sustainable weight loss solutions for their patients. As obesity rates continue to climb globally, including in regions like India where metabolic syndrome is prevalent, local practitioners must evaluate how international real-world data translates to their own patient populations.

Methodology of the Danish Primary Care Study

A recent retrospective observational study conducted in Denmark provides critical insights into these real-world dynamics. The researchers analyzed data from a single general practice, focusing on 206 adults who were prescribed semaglutide for weight management between December 2022 and May 2024. The cohort was predominantly female, comprising 76% of the participants, with a mean age of 48 years. At the start of the study, the mean baseline body weight was recorded at 105 kg. This study aimed to bridge the gap between clinical trial results and routine primary care outcomes by documenting exactly how the medication was being used in a non-experimental setting. Notably, the study focused on primary care, which is where the vast majority of obesity management occurs. By looking at real-world semaglutide weight management through this lens, the researchers could identify patterns in how physicians actually prescribe and how patients actually respond to the drug outside the strict confines of a protocol-driven study.

Analyzing Discontinuation and Treatment Persistence

One of the most significant findings from the Danish study was the high rate of treatment discontinuation. After 12 months, approximately 38% of the participants had permanently stopped using semaglutide. Furthermore, another 15% had paused their treatment temporarily. This means that fewer than half of the initial patients remained on the medication consistently throughout the year. In clinical trials, adherence is often artificially high due to frequent follow-ups and the absence of out-of-pocket costs. In contrast, real-world semaglutide weight management is frequently interrupted by side effects like nausea or vomiting, or by the significant financial burden associated with long-term use. Consequently, clinicians must be prepared for a high attrition rate and should focus on counseling patients about persistence. Managing expectations regarding the timeline of weight loss and the management of gastrointestinal symptoms is essential to improving long-term adherence in a general practice setting.

Titration Schedules: Deviating from the Label

The study also revealed that real-world titration schedules often deviate significantly from the manufacturer's recommended labeling. While the standard protocol suggests increasing the dose every four weeks until reaching a maintenance dose of 2.4 mg, the actual practice was much more conservative. Interestingly, 40% of the patients who remained on treatment were maintained on a dose of 1.0 mg or less per week. Only 30% reached the maximum approved dose of 2.4 mg. This slower and lower titration strategy is often a pragmatic response to patient tolerability. By staying at lower doses for longer periods, clinicians can often mitigate the adverse effects that lead to discontinuation. This suggests that real-world semaglutide weight management requires a more individualized approach than the "one size fits all" titration seen in clinical trials. Practitioners are clearly prioritizing patient comfort and long-term sustainability over rapid dose escalation, which may be a more realistic strategy for chronic disease management.

Weight Loss Efficacy in a Real-World Setting

Despite the slower titration and the use of lower maintenance doses, the efficacy of the medication remained impressive for those who stayed on the therapy. The study reported a relative mean body weight change of -13.6% after 12 months for those who had not discontinued the treatment. This result is particularly encouraging because it demonstrates that the clinical benefits of semaglutide are robust, even when the medication is not used exactly as prescribed in trials. Achieving a 13.6% reduction in body weight is clinically significant, as it is associated with major improvements in cardiovascular risk factors, glycemic control, and overall quality of life. For clinicians, this data reinforces the idea that semaglutide is a powerful tool in the fight against obesity, even when implemented with a flexible, patient-centered dosing strategy. It proves that real-world semaglutide weight management can yield substantial results that mirror those of high-resource clinical environments.

Clinical Implications for Healthcare Providers

The findings from this Danish study offer several valuable lessons for healthcare providers managing obesity. First, practitioners should expect that real-world titration will likely be slower than what is described in the product insert. This is not necessarily a failure of treatment but rather a necessary adaptation to ensure patient tolerance. Second, because discontinuation rates are high, there is a clear need for regular monitoring and support during the first few months of therapy. Moreover, the fact that significant weight loss occurred at lower doses suggests that clinicians do not always need to push for the maximum dose if the patient is already achieving meaningful progress and maintaining good tolerability. In a country like India, where many patients may be self-funding their treatment, using the lowest effective dose could also help with long-term affordability. Ultimately, successful real-world semaglutide weight management depends on a collaborative relationship between the doctor and the patient, focusing on long-term health outcomes rather than just the number on the scale.

Frequently Asked Questions

Why are discontinuation rates higher in real-world semaglutide use compared to clinical trials?

In clinical trials, patients benefit from intense monitoring, frequent contact with research staff, and free medication, which boosts adherence. In real-world settings, patients face practical barriers such as high costs and a lack of immediate support for side effects. Additionally, many patients in the community may stop the medication once they encounter gastrointestinal distress or reach a weight loss plateau, whereas trial participants are often encouraged to persist through these challenges.

Is it necessary to reach the 2.4 mg dose for effective weight management?

The Danish study suggests that reaching the maximum dose of 2.4 mg is not always required for clinical success. Many patients achieved a significant weight loss of over 13% while staying on doses of 1.0 mg or 1.7 mg. Clinicians should prioritize the "lowest effective dose" that the patient can tolerate. This approach helps minimize side effects while still providing the metabolic benefits necessary for long-term health improvement and sustainable weight reduction.

How should clinicians manage side effects to improve patient persistence?

Effective management of gastrointestinal side effects is crucial for improving treatment persistence. Clinicians should advise patients to eat smaller portions, avoid high-fat foods, and stay hydrated. If nausea occurs, extending the time between dose escalations or temporarily reducing the dose can be very helpful. Providing proactive guidance on over-the-counter anti-emetics and setting realistic expectations about the initial adjustment period can also prevent patients from prematurely discontinuing their real-world semaglutide weight management journey.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. The use of semaglutide should be managed by a licensed professional. Refer to the latest local and national guidelines for clinical practice.

References

Skandov MD et al. Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes. Diabetes Obes Metab. 2026 Jul 08. doi: 10.1111/dom.71092. PMID: 42420793.

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.

Ghusn W, et al. Weight Loss Outcomes Associated With Semaglutide in Patients With Overweight or Obesity: A Real-World Study. JAMA Netw Open. 2022;5(9):e2231245.